Clinical Trial Update: A Study of an FGFR2/3 Inhibitor (CGT4859) in Patients With Cholangiocarcinoma and Other Advanced Solid Tumors [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 study of CGT4859, an FGFR2/3 inhibitor, for intrahepatic cholangiocarcinoma, cholangiocarcinoma, and other advanced solid tumors; the study status is …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cholangiocarcinoma
• Intrahepatic Cholangiocarcinoma
• Solid Tumors

Drugs mentioned

• CGT4859

Snippet

Sponsor: Cogent Biosciences, Inc. | Conditions: Intrahepatic Cholangiocarcinoma (Icc), Cholangiocarcinoma | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING